Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety,
pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid
tumours where KRAS may be an important driver of tumour survival.
Part A: Dose escalation in patients with solid tumours to evaluate safety, pharmacokinetics
and maximum tolerated dose (MTD). Once the maximum tolerated dose (MTD) is established, a
dose expansion cohort may be included in Part A, with up to an additional 6 patients to
further explore the PK, safety, tolerability, and preliminary anti-tumour activity of the
AZD4785 MTD for confirmation of the recommended phase 2 dose (RP2D).
Part B: Expansion cohort at the selected dose in patients with non-small cell lung cancer
(NSCLC) to evaluate PK parameters, safety, tolerability, and preliminary anti-tumour activity
of the AZD4785 RP2D as monotherapy in patients with NSCLC. Approximately 20 patients with
NSCLC (Two groups of approximately 10 patients each) with NSCLC will be enrolled to Part B.
Group 1 patients will have an option to provide tumour biopsies and Group 2 will be required
(mandatory) to provide paired tumour biopsies. Overall up to 12 patients in Group 2Part B
patients will be required (mandatory) to may provide paired tumour biopsies. A third group of
up to 20 patients with other tumour types and/or a potential different schedule may be added
based on the results seen in Parts A and B and any other emerging data and may also provide
biopsies.
This is a First-Time-in-Human (FTIH), Phase 1 study to determine the MTD, recommended Phase 2
dose (RP2D), safety, tolerability, pharmacodynamics, and pharmacokinetics of AZD4785. The
study will be conducted in two parts: a dose-escalation phase (Part A)and an expansion phase
(Part B). A third group of up to 20 patients with other tumour types and/or a potential
different schedule may be added based on the results seen in Parts A and B and any other
emerging data.
AZD4785 will be given as an IV infusion over 1 hour, initially in 3 loading doses during the
first week and then weekly thereafter. The loading doses will be given on Days 1, 3, and 5 of
the first week and weekly thereafter on Days 8, 15, and 22 of 28 Day cycles. In subsequent
cycles AZD4785 will be administered on Days 1, 8, 15, and 22 until disease progression,
intolerable toxicity, or discontinuation criteria have been met.
Once the MTD is established, a dose expansion cohort may be included in Part A, with up to 6
additional patients to explore the PK, safety, tolerability, and preliminary anti-tumour
activity of the AZD4785 MTD for confirmation of the RP2D. Thereafter, Part B expansion phase
will continue to explore PK parameters, safety, tolerability, and preliminary anti-tumour
activity of the AZD4785 RP2D as monotherapy in patients with NSCLC. Approximately 20 patients
with NSCLC (2 groups of approximately 10 patients each) with NSCLC will be enrolled to Part
B. Group 1 patients will have an option to provide tumour biopsies and Group 2 will be
required (mandatory) to provide paired tumour biopsies. Overall up to 12 patients in Part B
may provide paired tumour biopsies. A third group of up to 20 patients with other tumour
types and/or a potential different schedule may be added based on the results seen in Parts A
and B and any other emerging data and may also provide biopsies. Up to 12 patients in Part B
may provide paired biopsies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |